44.00
+0.26(+0.59%)
Currency In USD
| Previous Close | 43.74 |
| Open | 43.93 |
| Day High | 44.82 |
| Day Low | 43.65 |
| 52-Week High | 62.4 |
| 52-Week Low | 25.93 |
| Volume | 735,258 |
| Average Volume | 1.58M |
| Market Cap | 8.02B |
| PE | -12.02 |
| EPS | -3.66 |
| Moving Average 50 Days | 50.99 |
| Moving Average 200 Days | 43.26 |
| Change | 0.26 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $1,522.49 as of January 03, 2025 at a share price of $44. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 3 years ago, it would be worth $1,681.96 as of January 03, 2025 at a share price of $44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire Inc.
Dec 05, 2024 9:05 PM GMT
Underwriters’ full exercise of option brings gross proceeds to $862.5 millionREDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for pati
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 04, 2024 3:38 AM GMT
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 sh
Revolution Medicines Announces Commencement of Public Offering of Common Stock
GlobeNewswire Inc.
Dec 02, 2024 9:31 PM GMT
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an unde